Status:
UNKNOWN
The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment
Lead Sponsor:
The Belgian Society of Medical Oncology
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
PRECISION 1 will enroll patients with metastatic solid tumors. The local PI will verify if the candidate patient fits the inclusion/ exclusion criteria. The participant will sign the PRECISION 1 info...
Eligibility Criteria
Inclusion
- Patients with metastatic solid tumors that are candidates for systemic therapy (early lines are preferred).
- Patient showing an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
- Patients able to provide written informed consent prior to enrollment into a subsequent clinical trial.
- Patients agrees to provide NGS data (somatic and/or germline) as well as clinical data baseline and during follow-up.
Exclusion
- Life expectancy of less than 12 weeks.
- Inability to comply with protocol procedures.
- Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according to the local PI).
- Targeted gene sequencing on DNA extracted from decalcified bone biopsies is not accepted.
Key Trial Info
Start Date :
March 31 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03873103
Start Date
March 31 2019
End Date
December 31 2023
Last Update
June 1 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
ZNA
Antwerp, Belgium, 2020
2
GZA
Antwerp, Belgium, 2610
3
AZ Klina
Brasschaat, Belgium, 2930
4
Institute Jules Bordet
Brussels, Belgium, 1000